John A. Zebala
Research Subjects
Research Interests
John A. Zebala has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Dean Y. Maeda
Syntrix Pharmaceuticals, Auburn, WA 98001, USA
42 shared publications - Jeffrey Schlom
Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
22 shared publications Angel P. Huynh
21 shared publicationsClaudia Palena
21 shared publicationsJay Friedman
21 shared publicationsLucas A. Horn
21 shared publications
Latest Publications
- 22 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
Gastric Mixed Neuroendocrine-Non-neuroendocrine Neoplasms Develop from POU2F3+ Multipotent Progenitors
Gastric mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) are aggressive malignancies that exhibit complex cellular heterogeneity driven by the dual lineages. The dismal patient survival rates highlight the need to elucidate the cellular origin of gastric MiNENs and the key regulatory mechanisms to develop improved treatment strategies. Here, we identified a gastric POU2F3+epithelial population as a potential cell of origin for gastric MiNENs. Lineage tracing and single-cell RNA sequencing further identified that POU2F3+ cells include three distinct subpopulations with divergent differentiation trajectories: progenitor cells (SOX2+SOX9+), tuft cells (POU2F3+DCLK1+), and neuroendocrine cells (SYP+CHGA+). Combined Rb1/Trp53 deletion and MYC overexpression in POU2F3+ epithelial cells (Pou2f3-CreERT; Rb1fl/fl; Trp53fl/fl; LSL-MycT58A) led to the rapid development of gastric MiNENs containing both neuroendocrine and non-neuroendocrine lesions, recapitulating human gastric MiNENs pathology. Transcription factor activity analysis and spatial transcriptomics revealed SOX2 and SOX9 as critical regulators driving subpopulation specification, with SOX2 and SOX9 being enriched in dysplasia and adenocarcinoma, respectively. Bulk RNA sequencing further showed increased expression of CXCL5 in gastric MiNENs, and inhibition of CXCL5 reduced the growth of tumor organoids and xenografts in mouse models. Together these findings offer a physiologically relevant model for studying gastric MiNENs and identify CXCL5 as a potential therapeutic target for this heterogeneous cancer.
- 22 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
Gastric Mixed Neuroendocrine-Non-neuroendocrine Neoplasms Develop from POU2F3+ Multipotent Progenitors
Gastric mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) are aggressive malignancies that exhibit complex cellular heterogeneity driven by the dual lineages. The dismal patient survival rates highlight the need to elucidate the cellular origin of gastric MiNENs and the key regulatory mechanisms to develop improved treatment strategies. Here, we identified a gastric POU2F3+epithelial population as a potential cell of origin for gastric MiNENs. Lineage tracing and single-cell RNA sequencing further identified that POU2F3+ cells include three distinct subpopulations with divergent differentiation trajectories: progenitor cells (SOX2+SOX9+), tuft cells (POU2F3+DCLK1+), and neuroendocrine cells (SYP+CHGA+). Combined Rb1/Trp53 deletion and MYC overexpression in POU2F3+ epithelial cells (Pou2f3-CreERT; Rb1fl/fl; Trp53fl/fl; LSL-MycT58A) led to the rapid development of gastric MiNENs containing both neuroendocrine and non-neuroendocrine lesions, recapitulating human gastric MiNENs pathology. Transcription factor activity analysis and spatial transcriptomics revealed SOX2 and SOX9 as critical regulators driving subpopulation specification, with SOX2 and SOX9 being enriched in dysplasia and adenocarcinoma, respectively. Bulk RNA sequencing further showed increased expression of CXCL5 in gastric MiNENs, and inhibition of CXCL5 reduced the growth of tumor organoids and xenografts in mouse models. Together these findings offer a physiologically relevant model for studying gastric MiNENs and identify CXCL5 as a potential therapeutic target for this heterogeneous cancer.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1-6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Table S7 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Table S7 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Table S2 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Table S2 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1_3to6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1_3to6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
- Open Access
Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies
Triple-negative breast carcinoma (TNBC) is one of the most aggressive types of solid-organ cancers. While immune checkpoint blockade (ICB) therapy has significantly improved outcomes in certain types of solid-organ cancers, patients with immunologically cold TNBC are afforded only a modest gain in survival by the addition of ICB to systemic chemotherapy. Thus, it is urgently needed to develop novel effective therapeutic approaches for TNBC. Utilizing the 4T1 murine model of TNBC, we developed a novel combination immunotherapeutic regimen consisting of intratumoral delivery of high-mobility group nucleosome binding protein 1 (HMGN1), TLR2/6 ligand fibroblast-stimulating lipopeptide (FSL-1), TLR7/8 agonist (R848/resiquimod), and CTLA-4 blockade. We also investigated the effect of adding SX682, a small-molecule inhibitor of CXCR1/2 known to reduce MDSC trafficking to tumor microenvironment, to our therapeutic approach. 4T1-bearing mice responded with significant tumor regression and tumor elimination to our therapeutic combination regimen. Mice with complete tumor regressions did not recur and became long-term survivors. Treatment with HMGN1, FSL-1, R848, and anti-CTLA4 antibody increased the number of infiltrating CD4+ and CD8+ effector/memory T cells in both tumors and draining lymph nodes and triggered the generation of 4T1-specific cytotoxic T lymphocytes (CTLs) in the draining lymph nodes. Thus, we developed a potentially curative immunotherapeutic regimen consisting of HMGN1, FSL-1, R848, plus a checkpoint inhibitor for TNBC, which does not rely on the administration of chemotherapy, radiation, or exogenous tumor-associated antigen(s).
Open AccessRegression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies
Triple-negative breast carcinoma (TNBC) is one of the most aggressive types of solid-organ cancers. While immune checkpoint blockade (ICB) therapy has significantly improved outcomes in certain types of solid-organ cancers, patients with immunologically cold TNBC are afforded only a modest gain in survival by the addition of ICB to systemic chemotherapy. Thus, it is urgently needed to develop novel effective therapeutic approaches for TNBC. Utilizing the 4T1 murine model of TNBC, we developed a novel combination immunotherapeutic regimen consisting of intratumoral delivery of high-mobility group nucleosome binding protein 1 (HMGN1), TLR2/6 ligand fibroblast-stimulating lipopeptide (FSL-1), TLR7/8 agonist (R848/resiquimod), and CTLA-4 blockade. We also investigated the effect of adding SX682, a small-molecule inhibitor of CXCR1/2 known to reduce MDSC trafficking to tumor microenvironment, to our therapeutic approach. 4T1-bearing mice responded with significant tumor regression and tumor elimination to our therapeutic combination regimen. Mice with complete tumor regressions did not recur and became long-term survivors. Treatment with HMGN1, FSL-1, R848, and anti-CTLA4 antibody increased the number of infiltrating CD4+ and CD8+ effector/memory T cells in both tumors and draining lymph nodes and triggered the generation of 4T1-specific cytotoxic T lymphocytes (CTLs) in the draining lymph nodes. Thus, we developed a potentially curative immunotherapeutic regimen consisting of HMGN1, FSL-1, R848, plus a checkpoint inhibitor for TNBC, which does not rely on the administration of chemotherapy, radiation, or exogenous tumor-associated antigen(s).
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
SHP2 inhibitors (SHP2i) alone and in various combinations are being tested in multiple tumors with overactivation of the RAS/ERK pathway. SHP2 plays critical roles in normal cell signaling; hence, SHP2is could influence the tumor microenvironment. We found that SHP2i treatment depleted alveolar and M2-like macrophages, induced tumor-intrinsic CCL5/CXCL10 secretion, and promoted B and T lymphocyte infiltration in Kras- and Egfr-mutant non–small cell lung cancer (NSCLC). However, treatment also increased intratumor granulocytic myeloid-derived suppressor cells (gMDSC) via tumor-intrinsic, NFκB-dependent production of CXCR2 ligands. Other RAS/ERK pathway inhibitors also induced CXCR2 ligands and gMDSC influx in mice, and CXCR2 ligands were induced in tumors from patients on KRASG12C inhibitor trials. Combined SHP2 (SHP099)/CXCR1/2 (SX682) inhibition depleted a specific cluster of S100a8/9hi gMDSCs, generated Klrg1+ CD8+ effector T cells with a strong cytotoxic phenotype but expressing the checkpoint receptor NKG2A, and enhanced survival in Kras- and Egfr-mutant models. Our results argue for testing RAS/ERK pathway/CXCR1/2/NKG2A inhibitor combinations in patients with NSCLC.Significance:Our study shows that inhibiting the SHP2/RAS/ERK pathway triggers NFκB-dependent upregulation of CXCR2 ligands and recruitment of S100A8hi gMDSCs, which suppress T cells. Combining SHP2/CXCR2 inhibitors blocks gMDSC immigration, resulting in enhanced Th1 polarization, induced CD8+KLRG1+ effector T cells with high cytotoxic activity, and improved survival in multiple NSCLC models.This article is highlighted in the In This Issue feature, p. 1
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
SHP2 inhibitors (SHP2i) alone and in various combinations are being tested in multiple tumors with overactivation of the RAS/ERK pathway. SHP2 plays critical roles in normal cell signaling; hence, SHP2is could influence the tumor microenvironment. We found that SHP2i treatment depleted alveolar and M2-like macrophages, induced tumor-intrinsic CCL5/CXCL10 secretion, and promoted B and T lymphocyte infiltration in Kras- and Egfr-mutant non–small cell lung cancer (NSCLC). However, treatment also increased intratumor granulocytic myeloid-derived suppressor cells (gMDSC) via tumor-intrinsic, NFκB-dependent production of CXCR2 ligands. Other RAS/ERK pathway inhibitors also induced CXCR2 ligands and gMDSC influx in mice, and CXCR2 ligands were induced in tumors from patients on KRASG12C inhibitor trials. Combined SHP2 (SHP099)/CXCR1/2 (SX682) inhibition depleted a specific cluster of S100a8/9hi gMDSCs, generated Klrg1+ CD8+ effector T cells with a strong cytotoxic phenotype but expressing the checkpoint receptor NKG2A, and enhanced survival in Kras- and Egfr-mutant models. Our results argue for testing RAS/ERK pathway/CXCR1/2/NKG2A inhibitor combinations in patients with NSCLC.Significance:Our study shows that inhibiting the SHP2/RAS/ERK pathway triggers NFκB-dependent upregulation of CXCR2 ligands and recruitment of S100A8hi gMDSCs, which suppress T cells. Combining SHP2/CXCR2 inhibitors blocks gMDSC immigration, resulting in enhanced Th1 polarization, induced CD8+KLRG1+ effector T cells with high cytotoxic activity, and improved survival in multiple NSCLC models.This article is highlighted in the In This Issue feature, p. 1
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1-6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S1_3to6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1_3to6 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC